Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%

Turn Therapeutics reported newly published, peer-reviewed preclinical results for GX-03 in a mouse model of dermatitis-like inflammation.

Findings were already presented via publication in Life, not flagged for a future medical meeting.

GX-03 pretreatment reduced inflammatory signaling tied to skin inflammation and itch, producing a selective effect rather than broad immune suppression.

Animals receiving GX-03 developed materially less severe dermatitis than untreated controls, supporting a prevention-oriented positioning in inflammatory skin disease.